Anticancer Therapies – Products

Sino Biological performs extensive quality control tests to ensure that GMP-grade cytokines meet rigorous quality standards, offering a range of GMP-grade cytokines

During this webinar, we will provide a comprehensive overview of several cytokine therapy approaches, development, and clinical application. We will further discuss how Sino Biological can assist in cancer immunotherapy research.

This whitepaper explores the role of extracellular vesicles in cell-to-cell communication during cancer progression. It also highlights a range of high-quality recombinant proteins, antibodies and cytokines and to support exosome research.

Although there are initiatives to de-risk the drug development process, continually applying the same tools and approaches is unlikely to lead to innovative, first- or best-in-class targets and transformative progress.

Oncodesign Services announces the execution of a Preclinical License and Supply Agreement with ImaginAb Inc. for the use of their investigational CD8 ImmunoPET™ (89Zr crefmirlimab berdoxam) technology.

Cell and gene therapies seek to correct the root cause of an illness at the molecular level. These game-changing medicines are reshaping how we address previously untreatable illnesses – transforming people’s lives.

Avacta Group plc has announced that the fifth dose escalation cohort in the ALS-6000-101 dose escalation Phase 1 clinical trial to evaluate the safety and tolerability of AVA6000 has been completed successfully.

RemeGen Co., Ltd announced the latest clinical research results on disitamab vedotin at this year's American Society of Clinical Oncology Annual Meeting.

As a global leader in the recombinant technology, Sino Biological provides a diverse array of recombinant proteins, antibodies, and ELISA kits to facilitate research and development of cancer treatments that focus on c-Kit and other RTKs (EGFR, VEGFR, PDGFR, c-Met, TrkB, FGFR, and more).

OncoHost has announced that it will give a poster presentation demonstrating the accuracy of its PROphet® biomarker model at the upcoming American Society of Clinical Oncology Annual Meeting, taking place June 2-6, 2023, in Chicago, Illinois.